Tuttle points to the FLOW trial's 24% relative risk cut in major kidney outcomes and lays out how guidelines add therapies one at a time.
Recap by typeshit. Full story at The American Journal of Managed Care.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
The AJC found clinics in Georgia promoting and dispensing copies of retatrutide, a drug that has not been approved. Tap through for how they are getting away with it.
Novo has lowered what it charges for Wegovy in China. Details on the size of the cut are in the full report.
Loading…